CRISPR Therapeutics AG

NasdaqGM:CRSP Stock Report

Market Cap: US$4.0b

CRISPR Therapeutics Management

Management criteria checks 3/4

CRISPR Therapeutics' CEO is Sam Kulkarni, appointed in Dec 2017, has a tenure of 6.92 years. total yearly compensation is $12.32M, comprised of 5.9% salary and 94.1% bonuses, including company stock and options. directly owns 0.33% of the company’s shares, worth $13.33M. The average tenure of the management team and the board of directors is 5.1 years and 5.4 years respectively.

Key information

Sam Kulkarni

Chief executive officer

US$12.3m

Total compensation

CEO salary percentage5.9%
CEO tenure6.9yrs
CEO ownership0.3%
Management average tenure5.1yrs
Board average tenure5.4yrs

Recent management updates

Shareholders Will Probably Hold Off On Increasing CRISPR Therapeutics AG's (NASDAQ:CRSP) CEO Compensation For The Time Being

May 23
Shareholders Will Probably Hold Off On Increasing CRISPR Therapeutics AG's (NASDAQ:CRSP) CEO Compensation For The Time Being

Recent updates

Crispr Therapeutics Q3 Earnings: No Casgevy Revenue, But Plenty Of Optimism

Nov 11

Here's What Analysts Are Forecasting For CRISPR Therapeutics AG (NASDAQ:CRSP) After Its Third-Quarter Results

Nov 07
Here's What Analysts Are Forecasting For CRISPR Therapeutics AG (NASDAQ:CRSP) After Its Third-Quarter Results

Crispr Therapeutics: Poised For A Major Turnaround

Oct 28

CRISPR Therapeutics AG (NASDAQ:CRSP) Investors Are Less Pessimistic Than Expected

Oct 02
CRISPR Therapeutics AG (NASDAQ:CRSP) Investors Are Less Pessimistic Than Expected

Crispr Therapeutics: Casgevy Now Active Across 35 Treatment Centres

Sep 13

Here's Why We're Not At All Concerned With CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Situation

Sep 04
Here's Why We're Not At All Concerned With CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Situation

Crispr's Casgevy Launch: Promising Start, Uncertain Future

Aug 14

A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)

Aug 09
A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)

Crispr Therapeutics Q2 Earnings: Casgevy Updates Underline 'Blockbuster' Potential

Aug 07

Crispr Therapeutics Remains Expensive, With Slower Casgevy Monetization And Patent Battle

Jul 13

Crispr Therapeutics: Beaten Down But Not Broken

Jul 07

CRISPR Therapeutics AG's (NASDAQ:CRSP) Share Price Could Signal Some Risk

Jun 18
CRISPR Therapeutics AG's (NASDAQ:CRSP) Share Price Could Signal Some Risk

Crispr Therapeutics, Futurism-Turning-Commercial, Defies 'Valuation' (Technical Analysis)

Jun 10

Crispr Therapeutics' Strategic Moves Amidst Gene Therapy Challenges (Rating Upgrade)

Jun 03

Shareholders Will Probably Hold Off On Increasing CRISPR Therapeutics AG's (NASDAQ:CRSP) CEO Compensation For The Time Being

May 23
Shareholders Will Probably Hold Off On Increasing CRISPR Therapeutics AG's (NASDAQ:CRSP) CEO Compensation For The Time Being

Newsflash: CRISPR Therapeutics AG (NASDAQ:CRSP) Analysts Have Been Trimming Their Revenue Forecasts

May 13
Newsflash: CRISPR Therapeutics AG (NASDAQ:CRSP) Analysts Have Been Trimming Their Revenue Forecasts

We're Not Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn

May 10
We're Not Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn

Crispr Therapeutics Q1 Earnings: Casgevy Launch Tip Of Gene Editing Iceberg

May 09

Crispr Therapeutics: Market Misunderstanding Is Your Buying Opportunity (Upgrade)

May 03

Crispr Therapeutics: Now Is The Time To Buy

Apr 24

Calculating The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)

Apr 16
Calculating The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)

Crispr Therapeutics: CASGEVY Commercial Launch Is Taking Shape

Mar 26

There's Reason For Concern Over CRISPR Therapeutics AG's (NASDAQ:CRSP) Massive 26% Price Jump

Feb 22
There's Reason For Concern Over CRISPR Therapeutics AG's (NASDAQ:CRSP) Massive 26% Price Jump

Crispr Therapeutics: Cautiously Optimistic

Feb 22

Crispr Therapeutics: Investors Bet Against Casgevy Uptake

Feb 01

Crispr Therapeutics: Commercial Validation Is The Next Step

Jan 18

Impact Of Gene Therapies And Casgevy On Crispr AG And The Industry

Jan 11

CRISPR Therapeutics AG's (NASDAQ:CRSP) Popularity With Investors Is Under Threat From Overpricing

Dec 25
CRISPR Therapeutics AG's (NASDAQ:CRSP) Popularity With Investors Is Under Threat From Overpricing

CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans

Nov 02
CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans

A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)

Oct 05
A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)

CRISPR Therapeutics AG's (NASDAQ:CRSP) Business Is Yet to Catch Up With Its Share Price

Sep 14
CRISPR Therapeutics AG's (NASDAQ:CRSP) Business Is Yet to Catch Up With Its Share Price

We're Not Very Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Rate

Jul 24
We're Not Very Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Rate

Calculating The Fair Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)

Jun 28
Calculating The Fair Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)

CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans

Apr 02
CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans

CRISPR Therapeutics AG's (NASDAQ:CRSP) Intrinsic Value Is Potentially 34% Above Its Share Price

Mar 06
CRISPR Therapeutics AG's (NASDAQ:CRSP) Intrinsic Value Is Potentially 34% Above Its Share Price

Companies Like CRISPR Therapeutics (NASDAQ:CRSP) Are In A Position To Invest In Growth

Dec 08
Companies Like CRISPR Therapeutics (NASDAQ:CRSP) Are In A Position To Invest In Growth

CRISPR CAR T cell therapy for skin/blood cancer gets FDA regenerative medicine tag

Sep 28

Crispr: Elucidating And Forecasting Key Developments

Sep 21

CEO Compensation Analysis

How has Sam Kulkarni's remuneration changed compared to CRISPR Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$240m

Jun 30 2024n/an/a

-US$266m

Mar 31 2024n/an/a

-US$217m

Dec 31 2023US$12mUS$725k

-US$154m

Sep 30 2023n/an/a

-US$354m

Jun 30 2023n/an/a

-US$416m

Mar 31 2023n/an/a

-US$524m

Dec 31 2022US$21mUS$700k

-US$650m

Sep 30 2022n/an/a

-US$681m

Jun 30 2022n/an/a

-US$633m

Mar 31 2022n/an/a

US$312m

Dec 31 2021US$17mUS$670k

US$378m

Sep 30 2021n/an/a

US$412m

Jun 30 2021n/an/a

US$447m

Mar 31 2021n/an/a

-US$392m

Dec 31 2020US$9mUS$625k

-US$349m

Sep 30 2020n/an/a

-US$211m

Jun 30 2020n/an/a

US$20m

Mar 31 2020n/an/a

US$46m

Dec 31 2019US$16mUS$550k

US$67m

Sep 30 2019n/an/a

-US$11m

Jun 30 2019n/an/a

-US$200m

Mar 31 2019n/an/a

-US$185m

Dec 31 2018US$10mUS$518k

-US$165m

Sep 30 2018n/an/a

-US$117m

Jun 30 2018n/an/a

-US$91m

Mar 31 2018n/an/a

-US$75m

Dec 31 2017US$7mUS$405k

-US$68m

Compensation vs Market: Sam's total compensation ($USD12.32M) is above average for companies of similar size in the US market ($USD6.60M).

Compensation vs Earnings: Sam's compensation has been consistent with company performance over the past year.


CEO

Sam Kulkarni (46 yo)

6.9yrs

Tenure

US$12,322,196

Compensation

Dr. Samarth Kulkarni, Ph D, also known as Sam, has been an Independent Director of Repare Therapeutics Inc. since November 2019. Dr. Kulkarni serves as Independent Director of Oruka Therapeutics, Inc since...


Leadership Team

NamePositionTenureCompensationOwnership
Samarth Kulkarni
CEO & Chairman6.9yrsUS$12.32m0.33%
$ 13.3m
Raju Prasad
Chief Financial Officer1.7yrsUS$5.91m0.012%
$ 472.8k
James Kasinger
General Counsel & Secretary7.5yrsUS$3.51m0.073%
$ 3.0m
Shaun Foy
Founderno datano datano data
Emmanuelle Charpentier
Co-Founder & Scientific Advisory Board Memberno datano datano data
Craig Mello
Scientific Founder & Advisory Board Memberno datano datano data
Chad Cowan
Scientific Founderno datano datano data
Matthew Porteus
Scientific Founder & Advisory Board Memberno datano datano data
Daniel Anderson
Scientific Founder & Advisory Board Memberno datano datano data
Julianne Bruno
Chief Operating Officerless than a yearno data0.016%
$ 653.9k
Stephen Kennedy
Head of Technical Operations5.1yrsno datano data
Susan Kim
Vice President of Corporate Communications & Investor Relationsno datano datano data

5.1yrs

Average Tenure

49yo

Average Age

Experienced Management: CRSP's management team is seasoned and experienced (5.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Samarth Kulkarni
CEO & Chairman6.4yrsUS$12.32m0.33%
$ 13.3m
Emmanuelle Charpentier
Co-Founder & Scientific Advisory Board Memberno datano datano data
Craig Mello
Scientific Founder & Advisory Board Memberno datano datano data
Matthew Porteus
Scientific Founder & Advisory Board Memberno datano datano data
Daniel Anderson
Scientific Founder & Advisory Board Memberno datano datano data
Douglas Treco
Lead Independent Director4.4yrsUS$552.56k0.0023%
$ 94.4k
Ali Behbahani
Independent Director9.6yrsUS$545.06k0.00032%
$ 12.9k
Katherine High
Independent Director5.4yrsUS$532.56k0%
$ 0
Simeon George
Independent Director9.6yrsUS$542.56k0%
$ 0
Stephen Elledge
Member of Scientific Advisory Boardno datano datano data
John Greene
Independent Director5.4yrsUS$555.06k0%
$ 0
H. Fleming
Independent Director3.4yrsUS$536.24k0%
$ 0

5.4yrs

Average Tenure

58yo

Average Age

Experienced Board: CRSP's board of directors are considered experienced (5.4 years average tenure).